New hope for lung cancer patients when standard pills fail

NCT ID NCT07181499

Recruiting now Disease control Sponsor: Betta Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 25 times

Summary

This study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to a class of targeted pills called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug (befotertinib), can help control the cancer longer. About 28 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Zhuhai, Guangdong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADJUVANT DRUG THERAPY EGFR EGFR NSCLC